High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein.
暂无分享,去创建一个
[1] S. Olson,et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. , 1992, The Journal of biological chemistry.
[2] C. W. Pratt,et al. A comparison of three heparin-binding serine proteinase inhibitors. , 1992, The Journal of biological chemistry.
[3] D. Mosher,et al. Inhibition of cell adhesion by high molecular weight kininogen , 1992, The Journal of cell biology.
[4] I. Cohen,et al. Anti-inflammatory effects of heparin and its derivatives: inhibition of complement and of lymphocyte migration. , 1992, Advances in experimental medicine and biology.
[5] A. Schmaier,et al. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. , 1991, The Journal of biological chemistry.
[6] S. Olson,et al. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects. , 1991, The Journal of biological chemistry.
[7] J. Griffin,et al. Interaction of Plasma Kallikrein with Protein C Inhibitor in Purified Mixtures and in Plasma , 1991, Thrombosis and Haemostasis.
[8] P. Singh,et al. Isolation of human blood coagulation alpha-factor Xa by soybean trypsin inhibitor-sepharose chromatography and its active-site titration with fluorescein mono-p-guanidinobenzoate. , 1989, Archives of biochemistry and biophysics.
[9] R. Colman,et al. Effect of Heparin on the Inhibition of the Contact System Enzymes , 1989, Annals of the New York Academy of Sciences.
[10] S. Olson,et al. Binding of heparin to human high molecular weight kininogen. , 1989, Biochemistry.
[11] B. Mulloy,et al. The anticoagulant activity of heparin: measurement and relationship to chemical structure. , 1989, Journal of pharmaceutical and biomedical analysis.
[12] H. Van Erp,et al. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. , 1988, Biochemistry.
[13] S. Olson,et al. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. Linkage of protease-inhibitor-heparin interactions in the reaction with thrombin. , 1988, The Journal of biological chemistry.
[14] K. Fujikawa,et al. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. , 1987, The Journal of biological chemistry.
[15] W. T. Morgan,et al. Histidine-rich glycoprotein modulation of the anticoagulant activity of heparin. Evidence for a mechanism involving competition with both antithrombin and thrombin for heparin binding. , 1987, The Journal of biological chemistry.
[16] S. Olson,et al. Acceleration of surface-dependent autocatalytic activation of blood coagulation factor XII by divalent metal ions. , 1987, Biochemistry.
[17] A. Retzios,et al. Effects of chemical modifications on the surface- and protein-binding properties of the light chain of human high molecular weight kininogen. , 1987, The Journal of biological chemistry.
[18] K. Fujikawa,et al. Identification of the binding site for plasma prekallikrein in human high molecular weight kininogen. A region from residues 185 to 224 of the kininogen light chain retains full binding activity. , 1986, The Journal of biological chemistry.
[19] M. Silverberg,et al. Study of the effect of high molecular weight kininogen upon the fluid-phase inactivation of kallikrein by C1 inhibitor. , 1986, The Journal of biological chemistry.
[20] J. Hall,et al. Reaction of thrombins with human antithrombin III. I. Enzyme activity losses unrelated to the inhibitory reaction and their prevention. , 1986, Thrombosis research.
[21] E. Davie,et al. Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA. , 1986, Biochemistry.
[22] F. Lottspeich,et al. Completion of the primary structure of human high-molecular-mass kininogen. The amino acid sequence of the entire heavy chain and evidence for its evolution by gene triplication. , 1986, European journal of biochemistry.
[23] J. Griffin,et al. Protein-protein interactions in contact activation of blood coagulation. Binding of high molecular weight kininogen and the 5-(iodoacetamido) fluorescein-labeled kininogen light chain to prekallikrein, kallikrein, and the separated kallikrein heavy and light chains. , 1985, The Journal of biological chemistry.
[24] S. Olson. Heparin and ionic strength-dependent conversion of antithrombin III from an inhibitor to a substrate of alpha-thrombin. , 1985, The Journal of biological chemistry.
[25] H. Maeda,et al. Interaction of factor XII, high-molecular-weight (HMW) kininogen and prekallikrein with sulfatide: analysis by fluorescence polarization. , 1985, Journal of biochemistry.
[26] A. Kaplan,et al. Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. , 1985, The Journal of biological chemistry.
[27] V. Turk,et al. Human plasma kininogens are identical with alpha-cysteine proteinase inhibitors. Evidence from immunological, enzymological and sequence data. , 1985, FEBS letters.
[28] N. Katunuma,et al. A new function of kininogens as thiol‐proteinase inhibitors: inhibition of papain and cathepsins B, H and L by bovine, rat and human plasma kininogens , 1985, FEBS letters.
[29] J. Catanese,et al. Primary structure of the reactive site of human C1-inhibitor. , 1985, The Journal of biological chemistry.
[30] R. Colman,et al. Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties. , 1985, Blood.
[31] K. Kurachi,et al. Isolation of a human cDNA for alpha 2-thiol proteinase inhibitor and its identity with low molecular weight kininogen. , 1984, Biochemistry.
[32] R. Colman. Surface-mediated defense reactions. The plasma contact activation system. , 1984, The Journal of clinical investigation.
[33] B. Bouma,et al. Interaction of human plasma kallikrein and its light chain with alpha 2-macroglobulin. , 1984, Biochemistry.
[34] J. Marcum,et al. Anticoagulantly active heparin-like molecules from vascular tissue. , 1984, Biochemistry.
[35] J. Shore,et al. Protein-protein interactions in contact activation of blood coagulation. Characterization of fluorescein-labeled human high molecular weight kininogen-light chain as a probe. , 1983, The Journal of biological chemistry.
[36] J. Griffin,et al. Immunologic studies of human coagulation factor XI and its complex with high molecular weight kininogen , 1983 .
[37] R. Harrison. Human C1 inhibitor: improved isolation and preliminary structural characterization. , 1983, Biochemistry.
[38] J. Griffin,et al. Interaction of human plasma kallikrein and its light chain with C1 inhibitor. , 1983, Biochemistry.
[39] D. Tollefsen,et al. Activation of heparin cofactor II by dermatan sulfate. , 1983, The Journal of biological chemistry.
[40] M. Hoylaerts,et al. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. , 1983, The Journal of biological chemistry.
[41] G. Salvesen,et al. Human plasma proteinase inhibitors. , 1983, Annual review of biochemistry.
[42] F van der Graaf,et al. Inactivation of kallikrein in human plasma. , 1983, The Journal of clinical investigation.
[43] I. Björk,et al. Production in vitro and properties of a modified form of bovine antithrombin, cleaved at the active site by thrombin. , 1982, The Journal of biological chemistry.
[44] S. Peltz,et al. P guanidino benzoic acid esters of fluorescein as active site titrants of serine proteases , 1982 .
[45] R. Colman,et al. Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen. , 1982, The Journal of clinical investigation.
[46] R. Colman,et al. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. , 1982, Biochemistry.
[47] R. Colman,et al. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. , 1982, The Journal of clinical investigation.
[48] J. Griffin,et al. The biochemistry and pathophysiology of the contact system of plasma. , 1982, Advances in immunology.
[49] S. Olson,et al. Binding of high affinity heparin to antithrombin III. Characterization of the protein fluorescence enhancement. , 1981, The Journal of biological chemistry.
[50] S. Nagasawa,et al. Studies on human high molecular weight (HMW) kininogen. II. Structural change of HMW kininogen by the action of human plasma kallikrein. , 1981, Journal of biochemistry.
[51] S. Iwanaga,et al. The role of bovine high-molecular-weight (HMW) kininogen in contact-mediated activation of bovine factor XII: interaction of HMW kininogen with kaolin and plasma prekallikrein. , 1981, Journal of biochemistry.
[52] S. Iwanaga,et al. [15] HMW and LMW kininogens , 1981 .
[53] E. Davie,et al. Bovine and human plasma prekallikrein. , 1981, Methods in enzymology.
[54] G M Oosta,et al. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. , 1980, The Journal of biological chemistry.
[55] J. Hirsh,et al. Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography. , 1980, Thrombosis research.
[56] S. Iwanaga,et al. Functional sites of bovine high molecular weight kininogen as a cofactor in kaolin-mediated activation of factor XII (Hageman factor). , 1980, Biochemistry.
[57] J. Griffin,et al. Immunochemical studies of human high molecular weight kininogen and of its complexes with plasma prekallikrein or kallikrein. , 1980, The Journal of biological chemistry.
[58] J. Griffin,et al. Human high molecular weight kininogen. Studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma. , 1979, The Journal of biological chemistry.
[59] M. Laskowski,et al. Purification of human plasma alpha 2 macroglobulin and alpha 1 proteinase inhibitor using zinc chelate chromatography. , 1979, Analytical biochemistry.
[60] A. Barrett,et al. The electrophoretically 'slow' and 'fast' forms of the alpha 2-macroglobulin molecule. , 1979, The Biochemical journal.
[61] S. Nagasawa,et al. Studies on human kininogens. I. Isolation, characterization, and cleavage by plasma kallikrein of high molecular weight (HMW)-kininogen. , 1979, Journal of biochemistry.
[62] M. Höök,et al. The molecular-weight-dependence of the anti-coagulant activity of heparin. , 1978, The Biochemical journal.
[63] J. Travis,et al. Purification of human α-2-macroglobulin by chromatography on Cibacron Blue Sepharose , 1978 .
[64] R. Roberts,et al. Physical and chemical properties of human plasma alpha2-macroglobulin. , 1978, The Biochemical journal.
[65] A. Kaplan,et al. Association of factor XI and high molecular weight kininogen in human plasma. , 1977, The Journal of clinical investigation.
[66] I. Björk,et al. The size and shape of human and bovine antithrombin III. , 1977, European journal of biochemistry.
[67] Robert B Sim,et al. A simplified procedure for the purification of C1̄‐inactivator from human plasma Interaction with complement subcomponents C1̄r and C1̄s , 1977, FEBS letters.
[68] R. Colman,et al. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[69] R. Colman. Hereditary Angioedema and Heparin Therapy , 1976 .
[70] J. Griffin,et al. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[71] J. Griffin,et al. [7] Human factor XII (Hageman factor) , 1976 .
[72] E. Thaler,et al. A Simple Two‐step Isolation Procedure for Human and Bovine Antithrombin II/III (Heparin Cofactor): a Comparison of Two Methods , 1975, British journal of haematology.
[73] P. Harpel. Separation of plasma thromboplastin antecedent from kallikrein by the plasma 2 -macroglobulin, kallikrein inhibitor. , 1971, The Journal of clinical investigation.
[74] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[75] J. Dunn,et al. The α2-Macroglobulin of Human Plasma I. ISOLATION AND COMPOSITION , 1967 .
[76] Ganrot Po. The combining ratio between trypsin and serum alpha-2-macroglobulin. , 1966 .